EN | UA
EN | UA

Help Support

Back

8-week glecaprevir and pibrentasvir combination therapy found effective for compensated cirrhosis

8-week glecaprevir and pibrentasvir combination therapy found effective for compensated cirrhosis 8-week glecaprevir and pibrentasvir combination therapy found effective for compensated cirrhosis
8-week glecaprevir and pibrentasvir combination therapy found effective for compensated cirrhosis 8-week glecaprevir and pibrentasvir combination therapy found effective for compensated cirrhosis

What's new?

Glecaprevir plus pibrentasvir can be safe and effective for treating compensated cirrhosis.

A direct-acting antiviral combination of glecaprevir and pibrentasvir was well-tolerated and effective in patients with compensated cirrhosis over a period of 8 weeks, a study in Liver international described. Researchers undertook this study to explore the efficacy and safety of glecaprevir/pibrentasvir therapy to treat compensated cirrhosis.

Overall, 187 hepatitis C virus-infected, treatment-naive, individuals with compensated cirrhosis were recruited for in this real-world analysis. They were given glecaprevir/pibrentasvir therapy for about eight weeks. In the per-protocol analysis, the sustained virologic response was found to be 98.4% (127/129) (not including participants lost to follow-up or who withdrew treatment because of compliance) while it was 85.8% (127/148) in patients with the data available in an intention-to-treat assessment.

A total of 19 patients were dropped to follow-up. A patient relapsed, and 1 succumbed to death, but these were not therapy-related. Headache and fatigue were witnessed by more than 5% of patients.

Although two serious adverse events ensued; but did not lead to drug stoppage. Thus, an eight-week glecaprevir/pibrentasvir therapy is effective and has good tolerability to treat people suffering from compensated cirrhosis. 

Source:

Liver international

Article:

Glecaprevir/pibrentasvir for 8 weeks in patients with compensated cirrhosis: safety and effectiveness data from the German Hepatitis C-Registry

Authors:

Hartwig Klinker et al.

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies en ru ua
Try: